Navigation Links
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
Date:2/29/2008

MADISON, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the end of its collaboration agreements with Solvay Pharmaceuticals for the development and commercialization of bifeprunox as well as other compounds in earlier stages of development for the potential treatment of schizophrenia and other psychiatric conditions.

Wyeth terminated the collaboration with Solvay after assessing the opportunity for bifeprunox and determining it would not have sufficient commercial value for the two companies to share.

All development and commercialization rights in North America for bifeprunox, an investigational atypical antipsychotic, as well as global rights for the other compounds will now revert to Solvay Pharmaceuticals.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Wyeth Announces Executive Change in Finance Organization
2. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
3. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
4. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
5. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
6. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
9. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
10. Wyeth Declares Preferred Stock Dividend
11. Wyeth Announces Election of New Principal Corporate Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Park Systems , world-leader in ... high vacuum AFM system in the market that meets ... manufacturing. Park NX-Hivac is ideal for academic and industrial ... highly doped semiconductor processing where more highly sophisticated failure ... vacuum scanning spreading resistance microscopy (SSRM) of Park NX-Hivac ...
(Date:5/6/2015)... 06, 2015 Histogen, Inc., a ... products of cells grown under simulated embryonic conditions, ... treatment candidate for melanoma during the 2015 Society ... May 6-9, 2015 in Atlanta, GA. , Histogen ... a soluble material with anti-oncologic properties, with potential ...
(Date:5/6/2015)... 2015 The Remedy Group , ... for the specialty pharmacy industry, will be exhibiting, presenting, ... Specialty Pharmacy Summit. The Summit will be held May ... and is the largest annual gathering for the specialty ... from pharmacy providers, pharma/biotech manufacturers, and payers, to learn ...
(Date:5/5/2015)... May 5, 2015  Blueprint Medicines (NASDAQ: ... initial public offering of 9,367,708 shares of common ... per share, including shares of common stock issued ... their option to purchase additional shares. The gross ... Medicines were approximately $168.6 million, before underwriting discounts and ...
Breaking Biology Technology:Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 2Park Systems Introduces Park NX-Hivac, a High Vacuum SSRM AFM System for Optimal Results in Semiconductor Manufacturing Failure Analysis 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2The Remedy Group presenting at the 2015 Armada Specialty Pharmacy Summit: The Pitfalls to Growth and Maintaining the Patient Experience 2Blueprint Medicines Announces Closing of Initial Public Offering 2
... CITY, Feb. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... company focused on,endocrine therapy and oncology, today reported ... agonist linked to doxorubicin,has commenced in its Phase ... had begun in December 2007. This open-label,non-comparative multi-center ...
... Candidates Featured -, SOUTH SAN FRANCISCO, Calif., ... company focused on the discovery,and development of monoclonal ... been selected for presentation at the meeting,of American ... Diego on,April 12-16, 2008., "We are pleased ...
... 12 Nektar,Therapeutics (Nasdaq: NKTR ) announced ... a drug delivery service provider to a,therapeutics drug ... corporate functions, and strengthen,decision-making and execution within the ... a world-class drug development company,and these changes are ...
Cached Biology Technology:AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 2AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 3AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 4Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 2Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations 3Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... A world-class St. Augustine spa called “perfect” by past ... a “perfect 10” business opportunity for entrepreneurs with an eye for beauty and ... Designed by renowned ... is part of the highly-rated Laterra Resort, located in the World Golf Village ...
... April 27 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... development company specialized in oncology and endocrinology, announced today that ... notifying it that the closing price per share of the ... bid price for 10 consecutive trading days and that, as ...
... be able to survive the harsh environs of Mars ... according to research published in the April 2010 issue ... The search for life on Mars remains a ... Institutes. To preserve the pristine environments, the bioloads on ...
Cached Biology News:Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 2Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 3Plastic Surgeons Rate Auction of World-Class Florida Laterra Spa May 21 a 'Perfect 10,' Great Business Opp for Celebrity Retreat 4
... microarrays containing peptidomimetics built on the ... synthesis platform. These microarrays are available ... Peptide Microarray Service. Custom ... completely customer specified. Thousands of customer ...
... OPEP-01009 is a 16 amino acid (amino acids 3-18) synthetic ... The sequence of this peptide is (amino to carboxy ... - V - K - L - R - A ... - K(18). This peptide may be used for ...
... is the industry standard microarray image analysis ... imaging and analysis tools, visualizations, automation capabilities, ... is included with every GenePix scanner, and ... scanners and all types of arrays. A ...
... Superior Protein Detection and Quantitation Over ... Proteomic Imaging System is a highly sensitive ... life science research applications. ProXPRESS 2D provides ... dyes in the UV and VIS spectrum ...
Biology Products: